Penghui Zhou Selected Research

Immune Checkpoint Inhibitors

1/2024	Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.
12/2023	Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.
11/2022	Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer.
1/2022	Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2.
1/2021	Fucoidan-Supplemented Diet Potentiates Immune Checkpoint Blockage by Enhancing Antitumor Immunity.
1/2021	The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
1/2018	Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Penghui Zhou Research Topics

Disease

31	Neoplasms (Cancer) 01/2024 - 12/2008
5	Melanoma (Melanoma, Malignant) 01/2023 - 03/2016
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 01/2020
3	Neoplasm Metastasis (Metastasis) 01/2024 - 10/2009
3	Microsatellite Instability 01/2021 - 01/2020
3	Prostatic Neoplasms (Prostate Cancer) 01/2015 - 02/2009
1	Autoimmune Diseases (Autoimmune Disease) 12/2022
1	Ovarian Neoplasms (Ovarian Cancer) 11/2022
1	Lung Neoplasms (Lung Cancer) 11/2022
1	Nausea 01/2022
1	COVID-19 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021
1	Carcinogenesis 01/2020
1	Kidney Neoplasms (Kidney Cancer) 01/2020
1	Liver Neoplasms (Liver Cancer) 01/2020
1	Methemoglobinemia 01/2020
1	Rhabdomyosarcoma 01/2020
1	Bites and Stings (Sting) 01/2019
1	Breast Neoplasms (Breast Cancer) 01/2017
1	Atherosclerosis 03/2016
1	Glioma (Gliomas) 01/2015
1	Dyslipidemias (Dyslipidemia) 03/2014
1	Experimental Melanoma 03/2014
1	Adenocarcinoma 10/2009
1	Genetic Predisposition to Disease (Genetic Predisposition) 10/2009

Drug/Important Bio-Agent (IBA)

7	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2018
5	AntigensIBA 11/2022 - 10/2009
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 02/2009
3	AntibodiesIBA 01/2021 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2021
2	InterferonsIBA 11/2022 - 01/2020
2	CytokinesIBA 11/2022 - 01/2020
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2015
2	Therapeutic UsesIBA 01/2022 - 01/2022
2	LipidsIBA 01/2021 - 03/2014
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2020
2	Monoclonal AntibodiesIBA 01/2020 - 02/2009
2	Chimeric Antigen ReceptorsIBA 01/2020 - 01/2017
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 10/2009
1	LisaftoclaxIBA 12/2023
1	AndrogensIBA 01/2023
1	carfilzomibIBA 11/2022
1	Small Cytoplasmic RNAIBA 01/2022
1	CannabinoidsIBA 01/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	VaccinesIBA 01/2022
1	Dronabinol (THC)FDA LinkGeneric 01/2022
1	LectinsIBA 01/2021
1	fucoidanIBA 01/2021
1	Calcibiotic Root Canal SealerIBA 01/2021
1	Clotrimazole (Lotrimin)FDA LinkGeneric 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2021
1	MethyltransferasesIBA 01/2021
1	Mevalonic Acid (Mevalonate)IBA 01/2021
1	Diacylglycerol KinaseIBA 01/2021
1	Angiogenesis InhibitorsIBA 01/2021
1	Monomeric GTP-Binding ProteinsIBA 01/2021
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	IpilimumabIBA 01/2020
1	Methylene Blue (Methylthioninium Chloride)FDA Link 01/2020
1	Interleukin-2 (IL2)IBA 01/2020
1	MutagensIBA 01/2020
1	Single-Chain AntibodiesIBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2020
1	EnzymesIBA 01/2020
1	Enhancer of Zeste Homolog 2 ProteinIBA 01/2020
1	MelatoninIBA 02/2019
1	LuciferasesIBA 02/2019
1	Proto-Oncogene Proteins B-rafIBA 02/2019
1	VemurafenibIBA 02/2019
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 02/2019
1	Epithelial Cell Adhesion MoleculeIBA 02/2019
1	GlucocorticoidsIBA 01/2019
1	A-Form DNA (A-DNA)IBA 01/2019
1	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2019
1	Topoisomerase II InhibitorsIBA 01/2019
1	HMGB1 Protein (HMG1)IBA 01/2019
1	Teniposide (VM 26)FDA Link 01/2019
1	Interferon Type IIBA 01/2019
1	CarcinogensIBA 01/2019
1	avasimibeIBA 03/2016
1	Small Interfering RNA (siRNA)IBA 01/2015
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 03/2014
1	AutoantibodiesIBA 03/2014
1	Lymphotoxin beta ReceptorIBA 10/2009
1	Immunoglobulin G (IgG)IBA 10/2009
1	Lymphotoxin-alpha (Lymphotoxin)IBA 10/2009
1	Tumor Viral Antigens (Large T Antigen)IBA 02/2009
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 12/2008
1	Glycogen Synthase Kinase 3 betaIBA 12/2008

Therapy/Procedure

21	Immunotherapy 01/2024 - 02/2009
14	Therapeutics 12/2022 - 02/2009
2	Drug Therapy (Chemotherapy) 01/2022 - 01/2017
1	Radiotherapy 01/2017
1	Molecular Targeted Therapy 01/2017